Arbutus Biopharma Corporation (ABUS)
NASDAQ·Healthcare·Biotechnology
$4.26
-0.23%
Mkt Cap $841.51M
Analyst Ratings
No recent rating data.
Price Target (1 analysts)
$8.50
Range $8.50 – $8.50
Implied Upside
+99.5%
Consensus $8.50 vs current $4.26
NASDAQ·Healthcare·Biotechnology
$4.26
-0.23%
Mkt Cap $841.51M
No recent rating data.
Price Target (1 analysts)
$8.50
Range $8.50 – $8.50
+99.5%
Consensus $8.50 vs current $4.26